Replimune Group, Inc.

Replimune Group, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its lead programs are built on the proprietary RPx platform and are designed to be used alone or in combination with other checkpoint blockade therapies, with development and eventual commercialization centered in the United States and potentially through partners in other geographies.

4.79

— Replimune Group, Inc.
%
RP1 and other product candidates0% Clinical-stage oncology biologics designed to stimulate anti-tumor immune responses.
RPx platform0% Proprietary oncolytic virus platform used to generate and advance cancer therapy candidates.
Clinical development programs0% Preclinical and clinical research activities supporting regulatory advancement of candidates.
Future product commercialization0% Potential sales and distribution of approved therapies in the United States and abroad.

Replimune does not yet sell approved products; its near-term customers are clinical investigators, trial sites,...

  • Clinical development ecosystemprimary

    Trial sites, investigators, CROs, and regulators that enable RP1 and other candidates to advance through studies and approvals.

  • Pharmaceutical and biotechnology partnerssecondary

    Potential collaborators for development, marketing, or regional commercialization outside the United States.

  • Oncology treatment providersprimary

    Hospitals, cancer centers, and oncologists that would prescribe approved therapies in future commercial use.

  • Payers and reimbursement decision makerssecondary

    Insurers and health plans that determine coverage and access for approved oncology products.

Replimune is headquartered in Woburn, Massachusetts and is organized in Delaware. Its core development and future...

  • •Headquartered in Woburn, Massachusetts, United States
  • •Organized as a Delaware corporation
  • •Primary commercialization focus is the United States
  • •Potential partnerships may support ex-U.S. markets
  • •FX exposure includes British pound sterling transactions

Replimune’s strategy is to advance RP1 and other RPx-based candidates through clinical development, secure regulatory...

01
Advance RP1 through clinical trials and approvalsshort-term

Clinical and regulatory success is the main path to first product revenue and platform validation.

02
Build commercialization infrastructureshort-term

Approved products require sales, marketing, distribution, and market access capabilities.

03
Secure scalable manufacturingmedium-term

Commercial supply and consistent quality are required for launch and broader adoption.

04
Expand the RPx platform and pipelinemedium-term

A broader pipeline can diversify clinical risk and create additional partnering opportunities.

Replimune faces the typical risks of a clinical-stage biotechnology company: uncertain trial outcomes, regulatory...

critical

Clinical development failure

RP1 and other candidates must prove safety and efficacy in trials before approval.

Scope
RP1 and future RPx candidates
Materiality
high
high

Regulatory approval and review risk

FDA and other agencies can delay, restrict, or deny marketing authorization.

Scope
Licensing applications and inspections
Materiality
high
high

Commercialization and reimbursement risk

Even approved oncology products may face slow adoption or limited coverage.

Scope
U.S. launch and payer access
Materiality
high
high

Manufacturing and supply chain risk

Biologic products require validated processes and reliable third-party supply.

Scope
Clinical and future commercial supply
Materiality
high
medium

Competition in oncology immunotherapies

Larger or better-funded companies may advance similar immune-oncology approaches faster.

Scope
Oncolytic viruses, neo-antigen vaccines, TILs, checkpoint combinations
Materiality
medium
medium

Cybersecurity and data privacy

Clinical and proprietary data are sensitive and attractive targets for attack.

Scope
Trial data, IP, and internal systems
Materiality
medium
Accrued research and development expenses
Can shift quarterly R&D expense and liabilities
Stock-based compensation
Affects operating expense and reported loss
Future revenue recognition
Will determine timing and classification of future revenue
Foreign currency transactions
Affects other income (expense), net

Evommune, Inc.

EVMN · Pharmaceutical Preparations

REPLIGEN CORP

RGEN · Biological Products, (No Diagnostic Substances)

Rezolute, Inc.

RZLT · Pharmaceutical Preparations

CG Oncology, Inc.

CGON · Biological Products, (No Diagnostic Substances)

SeaStar Medical Holding Corp

ICU · Surgical & Medical Instruments & Apparatus

ImageneBio, Inc.

IMA · Biological Products, (No Diagnostic Substances)

: 29.4.2026